Details of the Drug
General Information of Drug (ID: DMG2KI4)
Drug Name |
Fluocinolone Acetonide
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Therapeutic Class |
Antiinflammatory Agents
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Structure | ||||||||||||||||||||||||||||||||||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||||||||||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 452.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Choroiditis | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Fluocinolone acetonide FDA Label | ||||
---|---|---|---|---|---|
2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7077). | ||||
3 | Pharmacokinetics of fluocinolone acetonide in patch versus cream formulations. Int J Clin Pharmacol Res. 1991;11(1):17-21. | ||||
4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
5 | Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89. | ||||